A pooled analysis of transarterial radioembolization with yttrium-90 microspheres for the treatment of unresectable intrahepatic cholangiocarcinoma

Yanhua Zhen, Bin Liu, Zhihui Chang, Haiyan Ren, Zhaoyu Liu, Jiahe Zheng, Yanhua Zhen, Bin Liu, Zhihui Chang, Haiyan Ren, Zhaoyu Liu, Jiahe Zheng

Abstract

Purpose: The aim of this pooled analysis was to evaluate the clinical efficacy and safety of transarterial radioembolization (TARE) with yttrium-90 (90Y) microspheres for the treatment of unresectable intrahepatic cholangiocarcinoma (ICC). Methods: We searched the Cochrane Library, Embase, PubMed, SCI with the English language from inception to October 2018. A pooled analysis was conducted using Stata software. Results: There were 16 eligible studies included in this pooled analysis. The pooled median overall survival (OS) from 12 studies was 14.3 (95% CI: 11.9-17.1) months. Based on Response Evaluation Criteria in Solid Tumors (RECIST), no complete response was reported, and the median of partial response, stable disease and progressive disease were 11.5% (range: 4.8-35.3%), 61.5% (range: 42.9-81.3%) and 22.7% (range: 12.5-52.4%) respectively. The pooled disease control rate (DCR) from nine studies was 77.2% (95% CI: 70.2-84.2%). According to the type of microspheres, subgroup analysis was performed, the median OS in the glass microspheres group was 14.0 (95% CI: 9.1-21.4) months, and 14.3 (95% CI: 11.5-17.8) months in the resin microspheres group. The DCR was 77.3% (95% CI: 63.5-91.1%) and 77.4% (95% CI: 66.8-87.9%) in the glass and resin microspheres groups respectively. Most of the side effects reported in the included studies were mild and did not require intervention. Conclusion: TARE with 90Y microspheres is safe and effective for patients with unresectable ICC with acceptable side effects. And it seems that the type of microsphere has no influence on therapeutic efficacy.

Keywords: intrahepatic cholangiocarcinoma; pooled analysis; transarterial radioembolization; yttrium-90 microspheres.

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
A flowchart of study identification and selection.
Figure 2
Figure 2
Pooled analysis of median overall survival. Abbreviation: OS, overall survival.
Figure 3
Figure 3
Pooled analysis of disease control rate. Abbreviation: DCR, disease control rate.

References

    1. Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarcinoma. Ann Surg. 2008;248(1):84–96. doi:10.1097/SLA.0b013e318176c4d3
    1. Hogdall D, O'Rourke CJ, Taranta A, Oliveira DV, Andersen JB. Molecular pathogenesis and current therapy in intrahepatic cholangiocarcinoma. Dig Dis. 2016;34(4):440–451. doi:10.1159/000444562
    1. Ellis MC, Cassera MA, Vetto JT, Orloff SL, Hansen PD, Billingsley KG. Surgical treatment of intrahepatic cholangiocarcinoma: outcomes and predictive factors. Hpb. 2011;13(1):59–63. doi:10.1111/j.1477-2574.2010.00242.x
    1. Hong K, Geschwind J-FH. Locoregional intra-arterial therapies for unresectable intrahepatic cholangiocarcinoma. Semin Oncol. 2010;37(2):110–117. doi:10.1053/j.seminoncol.2010.03.002
    1. Yang L, Shan J, Shan L, Saxena A, Bester L, Morris DL. Trans-arterial embolisation therapies for unresectable intrahepatic cholangiocarcinoma: a systematic review. J Gastrointest Oncol. 2015;6(5):570–588. doi:10.3978/j.issn.2078-6891.2015.055
    1. Valle JW, Furuse J, Jitlal M, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol. 2013;25(2):391–398. doi:10.1093/annonc/mdt540
    1. Koay EJ, Odisio BC, Javle M, Vauthey J-N, Crane CH. Management of unresectable intrahepatic cholangiocarcinoma: how do we decide among the various liver-directed treatments? Hepatobiliary Surg Nutr. 2017;6(2):105–116. doi:10.21037/hbsn.2017.01.16
    1. Zheng J, Irani Z, Lawrence D, Flaherty K, Arellano RS. Combined effects of Yttrium-90 transarterial radioembolization around immunotherapy for hepatic metastases from uveal melanoma: a preliminary retrospective case series. J Vasc Interv Radiol. 2018;29(10):1369–1375. doi:10.1016/j.jvir.2018.04.030
    1. Al-Adra DP, Gill RS, Axford SJ, Shi X, Kneteman N, Liau -S-S. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. Eur J Surg Oncol (EJSO). 2015;41(1):120–127. doi:10.1016/j.ejso.2014.09.007
    1. Sara H, Downs NB. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377–384.
    1. Filippi L, Pelle G, Cianni R, Scopinaro F, Bagni O. Change in total lesion glycolysis and clinical outcome after (90)Y radioembolization in intrahepatic cholangiocarcinoma. Nucl Med Biol. 2015;42(1):59–64. doi:10.1016/j.nucmedbio.2014.08.011
    1. Beuzit L, Edeline J, Brun V, et al. Comparison of Choi criteria and response evaluation criteria in solid tumors (RECIST) for intrahepatic cholangiocarcinoma treated with glass-microspheres Yttrium-90 selective internal radiation therapy (SIRT). Eur J Radiol. 2016;85(8):1445–1452. doi:10.1016/j.ejrad.2016.05.020
    1. Gangi A, Shah J, Hatfield N, et al. Intrahepatic cholangiocarcinoma treated with transarterial Yttrium-90 glass microsphere radioembolization: results of a single institution retrospective study. J Vasc Interventional Radiol. 2018;29(8):1101–1108. doi:10.1016/j.jvir.2018.04.001
    1. Shaker TM, Chung C, Varma MK, et al. Is there a role for Ytrrium-90 in the treatment of unresectable and metastatic intrahepatic cholangiocarcinoma? Am J Surg. 2018;215(3):467–470. doi:10.1016/j.amjsurg.2017.11.022
    1. Camacho JC, Kokabi N, Xing M, Prajapati HJ, El-Rayes B, Kim HS. Modified response evaluation criteria in solid tumors and European Association for the study of the liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following Yttrium-90 radioembolization. J Vasc Interventional Radiol. 2014;25(2):256–265. doi:10.1016/j.jvir.2013.10.056
    1. Paprottka KJ, Schoeppe F, Ingrisch M, et al. Pre-therapeutic factors for predicting survival after radioembolization: a single-center experience in 389 patients. Eur J Nucl Med Mol Imaging. 2017;44(7):1185–1193. doi:10.1007/s00259-017-3646-z
    1. Orwat KP, Beckham TH, Cooper SL, et al. Pretreatment albumin may aid in patient selection for intrahepatic Y-90 microsphere transarterial radioembolization (TARE) for malignancies of the liver. J Gastrointest Oncol. 2017;8(6):1072–1078. doi:10.21037/jgo.2017.06.18
    1. Reimer P, Virarkar MK, Binnenhei M, Justinger M, Schön MR, Tatsch K. Prognostic factors in overall survival of patients with unresectable intrahepatic cholangiocarcinoma treated by means of Yttrium-90 radioembolization: results in therapy-naive patients. Cardiovasc Intervent Radiol. 2018;41(5):744–752. doi:10.1007/s00270-017-1871-2
    1. Swinburne NC, Biederman DM, Besa C, et al. Radioembolization for unresectable intrahepatic cholangiocarcinoma: review of safety, response evaluation criteria in solid tumors 1.1 imaging response and survival. Cancer Biother Radiopharm. 2017;32(5):161–168. doi:10.1089/cbr.2017.2189
    1. Soydal C, Kucuk ON, Bilgic S, Ibis E. Radioembolization with (90)Y resin microspheres for intrahepatic cholangiocellular carcinoma: prognostic factors. Ann Nucl Med. 2016;30(1):29–34. doi:10.1007/s12149-015-1026-y
    1. Jia Z, Paz-Fumagalli R, Frey G, Sella DM, McKinney JM, Wang W. Resin-based Yttrium-90 microspheres for unresectable and failed first-line chemotherapy intrahepatic cholangiocarcinoma: preliminary results. J Cancer Res Clin Oncol. 2017;143(3):481–489. doi:10.1007/s00432-016-2291-4
    1. Hoffmann RT, Paprottka PM, Schon A, et al. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol. 2012;35(1):105–116. doi:10.1007/s00270-011-0142-x
    1. Mouli S, Memon K, Baker T, et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol. 2013;24(8):1227–1234. doi:10.1016/j.jvir.2013.02.031
    1. Rafi S, Piduru SM, El-Rayes B, et al. Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study. Cardiovasc Intervent Radiol. 2013;36(2):440–448. doi:10.1007/s00270-012-0463-4
    1. Mosconi C, Gramenzi A, Ascanio S, et al. Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study. Br J Cancer. 2016;115(3):297–302. doi:10.1038/bjc.2016.191
    1. Saxena A, Bester L, Chua TC, Chu FC, Morris DL. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol. 2010;17(2):484–491. doi:10.1245/s10434-009-0777-x
    1. Cristina Mosconi AC, Ascanio S. Yttrium-90 microsphere radioembolization in unresectable intrahepatic cholangiocarcinoma. Future Oncol. 2017;13(15):1301–1310. doi:10.2217/fon-2017-0022
    1. Nezami N, Kokabi N, Camacho JC, Schuster DM, Xing M, Kim HS. (90)Y radioembolization dosimetry using a simple semi-quantitative method in intrahepatic cholangiocarcinoma: glass versus resin microspheres. Nucl Med Biol. 2018;59:22–28. doi:10.1016/j.nucmedbio.2018.01.001
    1. Ray CE Jr., Edwards A, Smith MT, et al. Metaanalysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma. J Vasc Interv Radiol. 2013;24(8):1218–1226. doi:10.1016/j.jvir.2013.03.019
    1. Boehm LM, Jayakrishnan TT, Miura JT, et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol. 2015;111(2):213–220. doi:10.1002/jso.23781
    1. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl_1):122S–150S. doi:10.2967/jnumed.108.057307
    1. Kim MN, Kim BK, Han KH, Kim SU. Volution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment. Expert Rev Gastroenterol Hepatol. 2015;9(3):335–348. doi:10.1586/17474124.2015.959929
    1. Haug AR, Heinemann V, Bruns CJ, et al. 18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres. Eur J Nucl Med Mol Imaging. 2011;38(6):1037–1045. doi:10.1007/s00259-011-1736-x
    1. Zerizer I, Al-Nahhas A, Towey D, et al. The role of early 18F-FDG PET/CT in prediction of progression-free survival after 90Y radioembolization: comparison with RECIST and tumour density criteria. Eur J Nucl Med Mol Imaging 2012;39(9):1391–1399. doi:10.1007/s00259-012-2149-1
    1. Lam MGEH, Banerjee S, Louie JD, et al. Root cause analysis of gastroduodenal ulceration after Yttrium-90 Radioembolization. Cardiovasc Intervent Radiol. 2013;36(6):1536–1547. doi:10.1007/s00270-013-0579-1

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere